Cidara Therapeutics (CDTX): Q3 GAAP EPS of -$0.08 beats by $0.18. Revenue of $19.1M beats by $13.1M. Press Release
Investing.com – U.S. stocks were lower after the close on Tuesday, as losses in the Industrials, Technology and Basic Materials sectors led shares lower. At the close in NYSE, the...
Cidara Therapeutics (CDTX -2.5%) announced the appointments of James (Jamie) Levine as CFO and Jessica Oien, J.D., as general counsel and secretary. Most recently, Mr. Levine...
Investors in Cidara Therapeutics, Inc. (NASDAQ:CDTX) need to pay close attention to the stock based on moves in the options market lately. That is because the Apr 20th 2018 $7.50...
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is expected to report third-quarter 2017 results around Nov 8, before market opens. Last quarter, Merrimack missed bottom-line...
Investors are always looking for stocks that are poised to beat at earnings season and Cidara Therapeutics, Inc. (NASDAQ:CDTX) may be one such company. The firm has earnings...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Sell||Buy||Sell|
|Technical Indicators||Strong Sell||Strong Sell||Strong Sell||Strong Buy||Strong Sell|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Buy||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Belt Hold Bullish||15||Current|
|Belt Hold Bullish||30||Current|
|Advance Block Bearish||1W||1||Nov 10, 2019|
|Three Outside Up||30||1||Nov 18, 2019 03:00PM|
|Bullish Engulfing||1D||2||Nov 14, 2019|
Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.Read More
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.